ClinicalTrials.gg
Active, not recruitingNCT06462222Updated Oct 20, 2026

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

A Phase 1/2 interventional study of Toripalimab, pemetrexed in Leptomeningeal Metastasis, sponsored by Guangzhou Medical University. Active, not recruiting at 5 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Guangzhou Medical University · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 20, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing pemetrexed in Meningeal Carcinomatosis — 6 open to participants now, 7 under way, none of them phase 3. Pemetrexed · Meningeal Carcinomatosis.

Enrollment
4th of 12
45 · median 35
Started
2024
with 4 others
Phase 1/2
3 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
3 of 12
Guangzhou Medical University

Among the 12 studies testing pemetrexed in Meningeal Carcinomatosis, this one is the 4th largest by enrollment, is one of 5 that started in 2024, is one of 3 in phase 1/2, and was the 10th registered.

Meningeal Carcinomatosis

146 studies on the registry are indexed under Meningeal Carcinomatosis; 48 are open to participants now.

Browse Meningeal Carcinomatosis studies →

Open to participants now

6 of the 12 studies testing pemetrexed in Meningeal Carcinomatosis are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 33 Meningeal Carcinomatosis studies recruiting now, 21 (64%) set no upper age limit and 10 (30%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing pemetrexed in Meningeal Carcinomatosis, or all of them as a file.
02

Study summary

This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors.

Read the detailed description

This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors. The primary objective was to assess recommended dose and safety based on adverse events (AEs). All participants were observed to evaluate the clinical response rate (CRR), disease control rate (DCR) and overall survival (OS). Patients underwent cerebrospinal fluid (CSF) and blood specimen collection to evaluate potential clinical, molecular, and/or immune predictors of treatment efficacy and safety.

03

Conditions studied

  • Leptomeningeal Metastasis

Keywords

  • Leptomeningeal metastasis
  • Intrathecal chemotherapy
  • Immune checkpoint inhibitor
  • Pemetrexed
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed diagnosis of solid tumors; Cerebrospinal fluid cytopathology is positive.
  2. Male or female aged between 18 and 75 years; Normal liver and kidney function; WBC≥4000/mm3, Plt≥100000/mm3.
  3. No history of severe nervous system disease; No severe dyscrasia.

Exclusion criteria

Exclusion Criteria:

  1. Any evidence of nervous system failure, including severe encephalopathy, grade 3 or 4 leukoencephalopathy on imaging, and Glasgow Coma Score less than 11.
  2. Any evidence of extensive and lethal progressive systemic diseases without effective treatment.
  3. A history of or AIDS, active or C infection, previous anti-PD1 therapy-induced pneumonitis, or have ongoing >Grade 2 adverse events of such therapy; or ongoing disease that required systemic treatment in the past 2 years.
  4. Patients with poor compliance or other reasons that were unsuitable for this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Group

    Immune checkpoint inhibitor combined with pemetrexed

    Drug: Toripalimab, pemetrexed

Interventions

06

What researchers measure

Primary outcomes

  1. Recommended dose

    The recommended dose of intrathecal PD-1 inhibitor. The dose limiting toxicity was defined as ≥ grade 3 neurological toxicities (e.g., chemical meningitis) or other grade 4 toxicity.

    Time frame: The dose limiting toxicity will be evaluated during the first 6 weeks of study treatment (the DLT window).

  2. Incidence of treatment-related adverse events

    The incidence of treatment-related adverse events were measured for determining tolerability and safety. Adverse events (AEs) are evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). Events of grade 3-5 are defined as moderate and severe adverse events.

    Time frame: From date of treatment until discontinuation of study treatment.

Other outcomes

  1. Clinical response rate

    The response assessment in neuro-oncology criteria (RANO) proposal for response criteria of leptomeningeal metastasis was used to assess the clinical response in this study.

    Time frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first.

  2. Progression-free survival related to leptomeningeal metastasis (LMPFS)

    LMPFS was defined as time from the enrollment until leptomeningeal metastasis progression or death, whichever occurred first. The leptomeningeal metastasis progression was determined based on the RANO proposal evaluation criteria which have been established and published on Neuro Oncol.

    Time frame: From enrollment to LM progression or death, whichever occurred first, or the last follow-up (at least 7 months).

  3. Overall survival(OS)

    Survival time was recorded since the date of patient enrollment. All patients were followed up until death or the end of the study.

    Time frame: From the enrollment of this study until date of death from any cause, whichever came first, or the last follow-up (at least 7 months).

  4. Disease control rate

    Disease control rate is defined as the proportion who achieve an leptomeningeal metastasis response or stable disease.

    Time frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first.

07

Study locations

5 sites
08

References and documents

Publications

  • Glitza Oliva IC, Ferguson SD, Bassett R Jr, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Carapeto FCL, Hudgens CW, Huse JT, Tetzlaff MT, Burton EM, Tawbi HA, Davies MA. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 Apr;29(4):898-905. doi: 10.1038/s41591-022-02170-x. Epub 2023 Mar 30. PubMed 36997799 ↗
  • Pan Z, Yang G, Cui J, Li W, Li Y, Gao P, Jiang T, Sun Y, Dong L, Song Y, Zhao G. A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer. Front Oncol. 2019 Aug 30;9:838. doi: 10.3389/fonc.2019.00838. eCollection 2019. PubMed 31544065 ↗

Individual participant data

Plan to share: Yes — All individual participant data that underlie results in a publication will be available to other researchers.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Starting 6 months after publication

Access criteria: Individual participant data will be public accessable via contacting with principal investigator by email within 6 months after the trial complete

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2024 (actual). Primary completion is estimated for Nov 2026, 29 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Sep 2026 → Nov 2026 and completion Sep 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Jun 17, 2024
StartActual
Jun 30, 2024
Primary completionEst.
Nov 2026was Sep 2026
CompletionEst.
Nov 2026was Sep 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Nov 2026
Oct 20, 2026
Study completion
Sep 2026→Nov 2026
Oct 20, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedA history of HIV or AIDS, acute or chronicactive hepatitis B or C infection, previous anti-PD1 therapy-induced pneumonitis, or have ongoing >Grade 2 adverse events of such therapy; or ongoing autoimmune disease that required systemic treatment in the past 2 years.
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Primary completion Sep 2026→Nov 2026
    Study completion Sep 2026→Nov 2026
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedA history of HIV or AIDS, acute or chronicactive hepatitis B or C infection, previous anti-PD1 therapy-induced pneumonitis, or have ongoing >Grade 2 adverse events of such therapy; or ongoing autoimmune disease that required systemic treatment in the past 2 years.

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06462222
Lead sponsor
Guangzhou Medical University
Collaborators
Jinshan Hospital Fudan University
Responsible party
Zhenyu Pan (Professor, Jinshan Hospital Fudan University) — Principal investigator
First posted
Jun 17, 2024
Start date
Jun 30, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Toripalimab · Pemetrexed

Start the discussion